Health & Fitness
Health and Fitness
Health and Fitness
Wed, May 18, 2011
Tue, May 17, 2011 Unigene Announces Presentations on Proprietary Recombinant Production and Oral Peptide Drug Delivery Technology at Upcoming 201
BOONTON, N.J.--([ BUSINESS WIRE ])--Unigene Laboratories, Inc. (OTCBB: UGNE) a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company will be presenting a poster and an oral presentation on its propriety recombinant production and oral peptide drug delivery technology during the upcoming 2011 [ TIDES: Oligonucleotide and Peptide® Research, Technology and Product Development ] Summit being held at the Hynes Convention Center and Sheraton Boston Hotel in Boston, MA from May 22 a" 25, 2011.
"Clinical Development Case Study: Optimizing a Solid Dosage Formulation for the Oral Delivery of Peptides"
Poster Presentation
Titled: aEscherichia coli High Yield Recombinant Expression, Secretion and Amidation of the 39 Amino Acid GLP-1 Analog Peptide Exendin-4a, and authored by Christopher P. Meenan, Frank V. Ritacco, Paul Van Duyne, Angelo P. Consalvo, Seth Pennington, Christina J. Sisk, Vicki L. Ray, and Nozer M. Mehta.
Oral Presentation
An oral presentation by Dr. Nozer Mehta, Unigenea™s Vice President Biological Research and Development, titledaClinical Development Case Study: Optimizing a Solid Dosage Formulation for the Oral Delivery of Peptidesa is scheduled to begin at 2:30 p.m. EDT on Wednesday, May 25, 2011.
Dr. Nozer Mehta, Vice President Biological Research and Development stated, "The TIDES Summit is considered one of the premier conferences focused on peptide based therapeutics. In the poster presentation, we are pleased to have the opportunity to showcase Unigenea™s high yield recombinant production technology as applied to Exendin-4, a currently marketed peptide. Our oral presentation highlights Unigenea™s tremendous progress in further optimizing our industry leading oral formulation by improving bioavailability, stability, and reducing variability. We will present data on the parameters of the optimization program that is the subject of a new patent application and the clinical use of the optimized tablets for the oral delivery of our PTH analog for the treatment of osteoporosis."
About Unigene Laboratories, Inc.
Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligencea" platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.
Unigenea™s technologies have extensive clinical and partner validation. The Companya™s first product to market, Fortical®, a nasal calcitonin product, received FDA approval in 2005 and is marketed in the U.S. by Upsher-Smith for the treatment of postmenopausal osteoporosis. Pivotal clinical programs include an oral calcitonin for the treatment of osteoporosis licensed to Tarsa Therapeutics, with an NDA filing expected in H2 2011. Other validating relationships include an oral parathyroid hormone currently in Phase 2 and licensed to GlaxoSmithKline. In addition, Unigene has a manufacturing license agreement with Novartis, which is completing three Phase 3 studies of oral calcitonin for the treatment of osteoporosis and osteoarthritis.
For more information about Unigene, please visit [ http://www.unigene.com ]. For information about Fortical, please visit [ http://www.fortical.com ].
